BioLife Solutions, Inc. provided revenue guidance for the year 2022. For the period, the company expects total revenue for 2022 is expected to range from $160 million to $166 million, reflecting year-over-year growth of 34% to 39% and organic growth of 37% to 43%. COVID-19 related revenue is expected to account for approximately 8% of total revenue.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
21.72 USD | +2.99% | -1.09% | +33.66% |
13/05 | Benchmark Upgrades BioLife Solutions to Buy From Hold With $25 Price Target | MT |
09/05 | Earnings Flash (BLFS) BIOLIFE SOLUTIONS Posts Q1 Revenue $31.7M, vs. Street Est of $24.9M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.66% | 100Cr | |
-5.56% | 18TCr | |
-0.11% | 11TCr | |
-6.17% | 6.61TCr | |
+2.64% | 5.07TCr | |
+6.58% | 4.31TCr | |
+3.40% | 4.13TCr | |
+21.98% | 3.16TCr | |
+16.81% | 2.5TCr | |
-5.81% | 2.42TCr |
- Stock Market
- Equities
- BLFS Stock
- News BioLife Solutions, Inc.
- BioLife Solutions, Inc. Provides Revenue Guidance for the Year 2022